WO1998029132A1 - Depistage precoce des maladies mycobacteriennes - Google Patents

Depistage precoce des maladies mycobacteriennes Download PDF

Info

Publication number
WO1998029132A1
WO1998029132A1 PCT/US1997/024189 US9724189W WO9829132A1 WO 1998029132 A1 WO1998029132 A1 WO 1998029132A1 US 9724189 W US9724189 W US 9724189W WO 9829132 A1 WO9829132 A1 WO 9829132A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
kda
early
tuberculosis
antigens
Prior art date
Application number
PCT/US1997/024189
Other languages
English (en)
Other versions
WO1998029132A9 (fr
Inventor
Suman Laal
Susan Zolla-Pazner
John T. Belisle
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Priority to EP97954653A priority Critical patent/EP0952849A4/fr
Priority to AU59051/98A priority patent/AU746752B2/en
Priority to CA002276491A priority patent/CA2276491C/fr
Publication of WO1998029132A1 publication Critical patent/WO1998029132A1/fr
Publication of WO1998029132A9 publication Critical patent/WO1998029132A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria

Definitions

  • a preferred embodiment of the above method includes, prior to step (b), the step of removing from the sample antibodies specific for antigens which are cross- reactive between Mt and other bacterial genera, such as by immunoadsorption of the sample with E. coli antigens.
  • the present invention also includes a method for the early detection of the presence of a mycobacterial disease or infection in a subject, comprising: (a) before the onset of symptoms identifiable as clinical disease, obtaining a biological fluid sample from the subject;
  • kits useful for early detection of an antibody specific for an early Mt antigen in a subject comprising
  • Figure 4 shows an immunoblot analysis of total LFCFP, and fractions 10 and 15.
  • Lanes 1, 5, and 9 contain molecular weight markers.
  • Lanes 2, 6 and 10 contain LAM-free CFP, lanes 3, 7 and 11 contain Mt fraction 10 and lanes 4, 8 and 12 contain Mt fraction 15.
  • the following antibody probes were used: lanes 1 to 4 were probed with pooled sera (1 :200) from ELISA + TB patients,; lanes 5-8 were probed with pooled sera from ELISA ne TB patients; lanes 9-12 were probed with pooled sera from PPD + , healthy controls.
  • Figure 14 shows a two dimensional PAGE of CFPs from M. tuberculosis H37Rv.
  • Known proteins are designated by the mAb or polyclonal sera that they reacted to by 2-D western blot analysis.
  • Unidentified proteins selected for N-terminal amino acid sequence are labeled A-K.
  • Figure 20 is a graph showing reactivity of sera from advanced (black bars) and early (gray bars) TB patients to M. tuberculosis LFCFP, purified Ag85C or purified MPT32.
  • Figures 22A and 22B show the hybridization of ⁇ gtl 1 (IT-57) with the katG gene.
  • Fig. 22A shows agarose gel electrophoresis of the DNA from ⁇ gtl 1 (IT-57) before (lane 2) and after digestion with EcoRl enzyme (lane 3); and plasmid pMD31 DNA containing the katG gene (lane 4) and after digestion with Kpnl and Xbal (lane 5).
  • Fig. 22B is a nitrocellulose blot of the gel of Fig. 22 A probed with 32 P-labeled insert DNA from the ⁇ gtl 1 (IT-57). The 1 kb DNA ladder is shown in lane 1 and the sizes of the fragments are shown on the right.
  • Figures 26A and 26B are graphs showing the reactivity of TB sera with Fraction F13, which is enriched for antigen MPT32.
  • Fig. 26 A shows reactivity with untreated F13.
  • Fig. 26B shows reactivity of sera with periodate-treated F13, in which glycosylation is destroyed by oxidation. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • the term “late” or “advanced” in reference to disease, infection, antibody response, antigen, or assay is characterized in that the subject has frank clinical disease and more advanced pulmonary lesions as well as presence of Mt bacilli in smears of sputum or other body fluids.
  • "Late TB” or “late mycobacterial disease” is used interchangeably with "advanced TB” or “advanced mycobacterial disease.”
  • An antibody appearing after the onset of diagnostic clinical symptoms is a late antibody, and an antigen recognized by a late antibody (but not by an early antibody) is a late antigen.
  • the antigen composition may be a substantially purified preparation of one or more M. tuberculosis proteins.
  • the antigen composition may be a partially purified or substantially pure preparation containing one or more M. tuberculosis epitopes which are capable of being bound by antibodies of a subject with TB.
  • Such epitopes may be in the form of peptide fragments of the early antigen proteins or other "functional derivatives" of M. tuberculosis proteins as described below.
  • a "chemical derivative" of the antigenic protein or peptide contains additional chemical moieties not normally part of the peptide.
  • Covalent modifications of the peptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
  • This protein is an Mt secreted protein having an apparent molecular mass of about 85kDa or about 88 kDa (depending in which of two different laboratories of the present inventors the determination is made). This protein is further characterized by an isoelectric point of about pH 5.2. This protein reacts with mAbs IT-42 and IT-57 and is a major antigenic component of Fraction 15 (Example I) and Fraction 14
  • a preferred binding partner for this assay is an anti-immunoglobulin antibody ("second antibody”) produced in a different species.
  • second antibody an anti-immunoglobulin antibody
  • a detectably labeled goat anti-human immunoglobulin "second” antibody may be used.
  • the solid phase support may then be washed with the buffer a second time to remove unbound antibody.
  • the amount of bound label on the solid support may then be detected by conventional means appropriate to the type of label used (see below).
  • the detectable label may be a radiolabel, and the assay termed a radioimmunoassay (RIA), as is well known in the art. See, for example,
  • agglutination assays both direct and indirect, which are well known in the art.
  • the agglutination of particles containing the antigen indicates the presence or absence of the corresponding antibody.
  • Any of a variety of particles, including latex, charcoal, kaolinite, or bentonite, as well as microbial cells or red blood cells, may be used as agglutinable carriers (Mochida, US 4,308,026; Gupta et al, J. Immunol. Meth. 80:177-187 (1985); Castelan et al, J. Clin. Pathol.
  • the antiserum can also be used in immobilized form as an immunoadsorbent in affinity purification of the antigen in accordance with standard methods in the art.
  • the antiserum can be used in an expression cloning method to detect the presence of the antigen in bacterial colonies or phage plaques where the antigen is expressed.
  • the antigen can be used to immunize animals to prepare high titer antisera or, preferably, to obtain a mAb specific for that antigen.
  • an animal antiserum or mAb can be employed advantageously in place of the patient antiserum or in combination with a test body fluid sample in a competition immunoassay.
  • the antiserum or mAb can be used for antigen production or purification, or in an immunoassay for detecting the antigen, for example as a binding partner (either the capture antibody or the detection antibody) in a sandwich immunoassay.
  • the present invention provides a method to detect immune complexes containing early Mt antigens in a subject using an EIA as described above. Circulating immune complexes have been suggested to be of diagnostic value in TB. (See, for example, Mehta, P.K. et al, 1989, Med. Microbiol. Immunol. 178:229-233; Radhakrishnan, V.V. et al, 1992, J. Med. Microbiol. 36: 128-131). Methods for detection of immune complexes are well-known in the art. Complexes may be dissociated under acid conditions and the resultant antigens and antibodies detected by immunoassay.
  • control populations consisted of the following groups: (a) 16 HIV ne , TB neg , PPD + healthy individuals (either recent immigrants from endemic countries or staff members involved in the care of TB patients in the VA Medical Center
  • CF was suspended (7mg/ml) in a buffer containing 50mM Tris HC1 (pH 7.4), and 150mM NaCl, following which 20% Triton X-114 was added to obtain a final concentration of 4%.
  • the suspension was allowed to rock overnight at 4°C.
  • a biphasic partition was set up by warming the 4% Triton X-114 suspension to 37°C for 40 minutes, followed by centrifugation at 12,000 x g.
  • the aqueous phase was re-extracted twice with 4% Triton X-114 to ensure complete removal of the lipoarabinomannan, lipomannan (LM) and phosphatidyl-inositol- mannoside (PIM).
  • LM lipomannan
  • PIM phosphatidyl-inositol- mannoside
  • This material (which contained the lipoglycans) was suspended in PBS and residual proteins were removed by extraction with PBS- saturated phenol. The aqueous phase was collected and, after dialyses against distilled water, the lipoglycans were lyophilized. LAM was further purified away from LM and PIM by size exclusion chromatography as previously described (Chatterjee, D. et al. , 1992, J. Biol. Chem. 269:66228-66233).
  • the CWC (mycolyl-arabinogalactan-peptidoglycan complex) was generated as described (Daffe, M. et al , 1990, J. Biol Chem. 265:6734-6743) with minor modifications.
  • the SDS-insoluble material obtained after extraction of the SCWP was suspended in PBS, 1% SDS, O.lmg/ml proteinase K and incubated for 20h at 50°C.
  • the insoluble material was pelleted by centrifugation, washed twice with 2% SDS at 95°C for lh and collected by centrifugation. This was washed several times with water and 80% acetone to remove SDS.
  • Fractionation of LFCFP by size was performed by using a preparative SDS- PAGE system (model 491 Prep cell, Bio-Rad, Hercules, CA).
  • CFP (20-25 mg) was loaded directly onto a 30ml 10% preparative polyacrylamide tube gel containing a 6% stacking gel, that was poured in a casting tube with a 37mm internal diameter.
  • the running buffer used consisted of 25mM Tris, pH 8.3, 192mM glycine, 0.1% SDS.
  • the proteins were separated by electrophoresis using an increasing wattage gradient of 8W for 3.13h, 12W for 2.5h, and finally 20W for 1 l.lh.
  • IT-41 F15 IT-41, IT-57 73 Specificity of murine mAbs: IT-62 and IT-23 are anti-38 kDa; IT-41 is anti-71 kDa;
  • IT-57 is anti-82 kDa.
  • Anti-MPT32 antiserum was raised in rabbits.
  • the ELISA + TB serum pool recognized at least 10 additional distinct bands in the fractionated total LFCFP ( Figure 4, lane 2).
  • the molecular weights of the antigens ranged from 33kDa to 112kDa.
  • the 38kDa antigen was the most dense band observed, indicating that it is the most abundant antigen recognized by this serum pool in the LFCFP. Since it is a strongly seroreactive antigen in several patients
  • Fraction 10 contained large amounts of the 38 kDa antigen, which was the strongest band, and smaller amounts of other seroreactive proteins ranging from 30- 43kDa.
  • fraction 15 contained several high molecular weight antigens ranging from 72-88 kDa, and a small amount of the 38kDa antigen (which was not detected by anti-38 kDa mAbs, Table 3). Strong seroreactivity with a doublet at 88- 84kDa, and weaker reactivity with 78kDa and 72kDa antigens was seen.
  • the diagnosis of TB was based on positive cultures for M. tuberculosis. Sera from 20 non-HIV TB patients (non-HIV/TB), 19 of whom were smear- positive, and all of whom showed radiological evidence of moderate to advanced cavitary disease, were included as positive controls. Sera from 19 non-HIV/ PPD skin test-positive individuals were included as negative controls. To rule out nonspecific reactivity, the study included (i) sera from 35 HIV-infected, asymptomatic individuals, with CD4 cell counts >800 and (ii) 48 serum samples from 16 HIV- infected subjects whose blood cultures were positive for Mycobacterium avium- intracellulare ("HIV/MAI". Of these, 28 HIV/MAI serum samples were obtained during the months preceding advent of MAI bacteremia.
  • the repertoire of M tuberculosis antigens which elicit antibodies in the HIV/TB patients is limited in comparison to non-HIV/TB patients: antibodies to several antigens with molecular weights of 32-45 kDa are absent in these HIV/TB patients. Antibodies to a strongly seroreactive 38 kDa antigen, which are present in 50-60%) of non-HIV/TB TB patients, were absent from most HIV/TB patients.
  • Example I shows that the 88 kDa antigen (present in Fraction 15 in that study, but present in Fraction 14 in the study of Example II) is one of the secreted antigens of M tuberculosis that elicits antibodies during early stages of disease progression (in non-HIV TB patients).
  • the detection of anti-88 kDa antibodies in the high risk HIV-infected population can serve as a diagnostic test, and the antibody as a surrogate marker, for identifying individuals with active pre-clinical TB.
  • PPD + Draggerald J.M. et al, Chest 700:191-200
  • N-terminal sequencing of the ⁇ -mannosidase digested form of this S 22 peptide produced a sequence identical to that obtained for the naturally occurring non-glycosylated S 33 peptide (GEVAPTPTTPTPQ; SEQ ID NO:25), confirming that the S 22 glycopeptide was O-glycosylated at the third Thr residue.
  • Similar analyses of the two other glycopeptides of the S 22 cluster confirmed that one (m/z 1781.9) was glycosylated with three ⁇ -Man residues and the other (m/z 1457.6) with a single ⁇ -Man residue.
  • Analysis of the (oligo)glycosyl alditols further demonstrated heterogeneous glycosylation of the peptide with ⁇ -Man, ( ⁇ l-2)- mannobiose or ( ⁇ l-2)-mannotriose.
  • the S 41 glycopeptide was shown to be O-glycosylated at the position 10 Thr residue.
  • ⁇ -Mannosidase digestion followed by N-acetylation, methyl esterification and FAB-MS analysis produced (M+H) + pseudomolecular ion of m/z 1297.6, indicating the loss of two ⁇ -Man residues.
  • the oligoglycosylalditol released from the S 41 glycopeptide was found to be comprised of a pre-reduced 2- linked mannitol and a terminal Man (Table 6).Thus, the Thr residue at position 10 of this peptide was glycosylated with an ( ⁇ l -2)-linked mannobiose.
  • Mannosylation of mycobacterial proteins may bear similarities to that of the yeast mannoproteins.
  • the di- and tri-mannosyl units of the 45 kDa glycoprotein are identical to the "mannose caps" of mycobacterial LAM (the so-called Man-LAM) in absolute configuration and linkage (Chatterjee, D. et al, 1992, J. Biol. Chem. 267:6234-6239), suggesting that the enzymatic machinery is shared by both systems.
  • the mannosyl units of the 45 kDa protein may share a role in the phagocytosis of M tuberculosis, analogous to that of the Man-LAM (Schlesinger, L.S. et al, 1994, J. Immunol. 752:4074-4079).
  • the column was washed with 3 vol of storage buffer at a flow rate of 1 ml/min which eluted the majority of proteins while leaving the Ag85 complex bound to the Phenyl Sepharose matrix.
  • the individual proteins of the Ag85 complex were eluted with 30 ml of buffer A (10 mM Tris HC1 pH 8.6, 1 mM DTT, 1 mM EDTA) followed by a linear gradient composed of 100% buffer A to 100% buffer B
  • the present inventors have combined 2-D PAGE, western blot analysis, N-terminal amino acid sequencing and liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) to develop a detailed map of culture filtrate proteins and have obtained the partial amino acid sequences for five previously undefined, relatively abundant proteins within this fraction which are found to be useful as early antigens for serodiagnosis of TB.
  • LC-MS-MS liquid chromatography-mass spectrometry-mass spectrometry
  • Mt strains H37Rv (ATCC 27294) and H37Ra (ATCC 25177) were obtained from American Type Culture Collection (Rockville, MD). Mt strain Erdman (TMC) was obtained from American Type Culture Collection (Rockville, MD). Mt strain Erdman (TMC).
  • Protein content of the concentrated culture filtrate was quantitated by the bicinchoninic acid protein assay.
  • culture tubes 13 by 100 mm
  • 3 ml of GAS media with 0.05% Tween 80 were inoculated with actively growing Mt cultures to an optical density of 0.1 at 600 nm. These cultures were incubated at 37°C with stirring and optical densities at A600 were obtained every 12 hours for a 22 day period.
  • the mAbs IT-69 (HBT11) and IT-67 (L24.b4) were obtained from Dr. Ase B. Andersen, Statens Seruminstitut, Copenhagen, Denmark.
  • the mAb A3h4 was obtained from Drs. P.K. Das and A. Rambukana, University of Amsterdam, Amsterdam, The Netherlands and mAbs F 126-2 and HYB 76-8 were obtained from
  • SDS-PAGE and 2-D PAGE of Culture Filtrate Proteins SDS-PAGE was performed under reducing conditions by the method of Laemmli with gels (7.5 x 10 cm x 0.75 mm) containing a 6% stack over a 15% resolving gel. Each gel was run at 10 mA for 15 min followed by 15 mA for 1.5 h. 2-D PAGE separation of proteins was achieved by the method of O'Farrell with minor modifications.
  • Electrophoresis in the second dimension was carried out at 20 mA per gel for 0.3 h followed by 30 mA per gel for 1.8 h. Proteins were visualized by staining with silver nitrate. 4. Computer Aided Analysis of Two-Dimensional Gels
  • CFPs 200 ⁇ g were resolved by 2-D PAGE and transferred to poly vinylidene difluoride membrane (Millipore, Milford, Mass.) by electroblotting at 50 V for 1 h, using CAPS buffer with 10% methanol. The membrane was stained with 0.1 % Coomassie brilliant blue in 10% acetic acid and destained with a solution of 50% methanol and 10% acetic acid. Immobilized proteins were subjected to automated Edman degradation on a gas phase sequencer equipped with a continuous-flow reactor. The phenylthiohydantoin amino acid derivatives were identified by on-line reversed-phase chromatography as described previously.
  • IT-43, IT-44, IT-45, IT-51, IT-52, IT-53, IT-57, IT-59 and IT-69 were selected and subjected to N-terminal amino acid sequencing ( Figure 14 and Table 8). Three of these proteins were found to correspond to previously defined products.
  • the N-terminal amino acid sequence of the protein labeled D was identical to that of Ag85 B and C. This result was unexpected given that the IT-49 mAb failed to detect this protein and N-terminal amino acid analysis confirmed that those proteins reacting with IT-49 were members of the Ag85 complex.
  • the protein labeled E had an N-terminal sequence identical to that of glutamine synthetase.
  • a third protein which reacted with IT-52 was found to be identical to MPT 51.
  • the protein labeled I possessed an N- terminal sequence with 72% identity to the amino terminus of an ⁇ -hydroxysteroid dehydrogenase from a Eubacterium species , and the protein labeled F was homologous to a deduced amino acid sequence for an open reading frame identified in the Mt cosmid MTCYl Al 1. Repeated attempts to sequence those proteins labeled as A, G, H, J, K, IT-43, IT-44, IT-49 and IT-57 were unsuccessful.
  • Examples I and II show that a high molecular weight fraction of CFP of Mt reacted with a preponderance of sera from TB patients and that this fraction was distinguished from other native fractions in that it possessed the product reactive to mAb IT-57.
  • the protein cluster (the 88 kDa protein) defined by IT-42 and IT-57 was excised from a 2-D polyacrylamide gel, digested with trypsin and the resulting peptides analyzed by LC-MS-MS.
  • Ten of the peptides from the digest yielded molecular masses and fragmentation patterns consistent with those predicted for tryptic fragments of the Mt KatG catalase/peroxidase (Table 8).
  • Strain H37Rv contained three apparently strain-specific proteins, numbered 9, 123 and 203 ( Figure 15A and 15B and Table 9). Similarly, the proteins numbered 206, 207, 208 and 209 were apparently specific for H37Ra ( Figure 15C and " 15D and Table 9) and twelve strain specific proteins, numbered 211-222, were associated with the CFP of the Erdman strain ( Figures 15E and 15F and Table 9). However, of the proteins apparently limited to Erdman, only 212, 210, 220, 221 and 222 were exclusive. The other seven were also present in H37Rv but at quantities below the preset software values for peak height and area detection levels. Several proteins were associated with two of the three type strains. Proteins numbered 8, 39, 62, 71, 108, 121, 138, 191, 197, 199, 202 and 204 were specific for H37Rv and
  • Protein 151 and 210 were present in the culture filtrate of Mt H37Rv and Erdman, and H37Ra and Erdman, respectively.
  • Protein 151 identified by its reactivity with mAb IT-45 and its absence from H37Ra secreted proteins, was confirmed by 2-D Western blot analysis In sum, proteins present only in one or two of the type strains were relatively minor components of the culture filtrates ( Figures 15 A-F). Their appearance and the resultant 2-D profile differences could have been caused by disparate growth rates or cellular autolysis during culture. The lack of detectable 65 kDa GroEL homologue, a marker for autolysis, in the present preparations discounted the possibility of autolysis.
  • Table 9 Summary of protein spots detected by computer aided analysis of silver nitrate stained 2-D gels.
  • Table 9 Summary of protein spots detected by computer aided analysis of silver nitrate stained 2-D gels.
  • Table 9 Summary of protein spots detected by computer aided analysis of silver nitrate stained 2-D gels.
  • Table 9 Summary of protein spots detected by computer aided analysis of silver nitrate stained 2-D gels.
  • Table 9 Summary of protein spots detected by computer aided analysis of silver nitrate stained 2-D gels.
  • the CFPs are well defined in terms of function, immunogenicity and composition.
  • a detailed analysis of the total proteins, and the molecular definition and 2-D PAGE mapping of the majority of these CFPs has not been performed.
  • Nagai and colleagues identified and mapped by 2-D PAGE the most abundant proteins filtrate harvested after five weeks of culture in Sauton medium.
  • the present study used culture filtrates from mid- to late-logarithmic cultures of three Mt type strains H37Ra, H37Rv, and Erdman to provide for the first time a detailed analysis understanding of this widely studied fraction.
  • a second product sequenced was a 25 kDa protein with a pi of 5.34. Its N- terminal sequence (XPVM/LVXPGXEXXQDN, [SEQ ID NO: 100]) showed homology to an internal fragment (DPVLVFPGMEIRQDN, [SEQ ID NO: 105]) corresponding to open reading frame 28c of the Mt cosmid MTCYl Al 1. Analysis of that deduced sequence revealed a signal peptidase I consensus sequence (Ala-Xaa- Ala) and an apparent signal peptide preceding the N-terminus of the 25 kDa protein sequenced above
  • the mAb IT-57 recognized an 88 kDa band in the LFCFP (Fig. 21, lane 2), and in the lysate of E. coli lysogen of ⁇ gtl 1 (IT-57) (lane 3). No proteins in the lysate from the E. coli 1089 lysogenized with the wild type ⁇ gtl 1 reacted with the mAb
  • FIG. 22a is an autoradiograph showing that the 3.2 kb insert from ⁇ gtl 1 (IT-57) hybridized with itself (lane 3), and with both the uncut pMD31 vector containing the katG gene (lane 4) and the katG insert DNA itself (2.9 kb, lane 5). Therefore, the 88 kDa antigen reactive with mAb IT-57 is in fact the catalase/peroxidase enzyme.
  • the / ⁇ tG-negative BCG strain 35747 transformed with either the pMD31 :M. tuberculosis katG or with the control pMD31 plasmid (vector control) were tested.
  • tuberculosis katG and the katG-negative BCG containing pMD31 were separated by SDS-PAGE polyacrylamide on 10% gels (Figure 23).
  • the fractionated proteins were transferred to nitrocellulose filters and probed with an anti- catalase/peroxidase polyclonal serum (obtained from Dr. Clifton Barry, Rocky Mountain Laboratories, NIAID, Hamilton, MT) (Fig.23A), mAb IT-57 (Fig. 23B), mAb IT-42 (Fig. 23C) and serum from an advanced TB patient (Fig. 23D).
  • the anti- catalase/peroxidase polyclonal serum and the mAb IT-57 reacted strongly with an 88 kDa antigen in the LFCFP, in the M. tuberculosis katG containing M. bovis BCG and in E. coli ⁇ gtl 1 (IT-57).
  • MAb IT-42 reacted with the same bands in the LFCFP and the M. tuberculosis katG BCG, but not with the 88 kDa protein expressed in E. coli.
  • the serum from the tuberculosis patient recognized an 88 kDa antigen in the lysates of the katG-negative BCG strain. This is evidence that the seroreactive 88 kDa antigen is a novel protein which has not been previously described.
  • M. tuberculosis also contains a seroreactive 88 kDa antigen which is not the catalase/peroxidase, a / ⁇ tG-negative strain of M. tuberculosis
  • Example I Culture filtrates from log phase Mt H 37 Rv were used as the source of secreted antigens as described in Example I (LAM-free culture filtrate proteins or CFPs).
  • the LFCFP preparation contained over 200 proteins (Example V, supra).
  • Antigens were size fractionated by loading onto a preparative polyacrylamide tube gel, and proteins were separated by electrophoresis using an increasing wattage gradient (model 491 Prep Cell; Bio-Rad, Hercules, CA.). Fractions were collected, assayed by SDS-PAGE and pooled according to molecular weights. Contaminating SDS was removed as described above. Reactivity of each fraction with human sera and an extensive panel of murine mAbs to Mt antigens are described in Example I.
  • Fractions containing the 38 (or 35) kDa PstS and the seroreactive 88 kDa antigen were identified by reaction with anti-38 kDa mAb IT-23 and mAbs IT-57 and IT-42, respectively.
  • Immunoadsorption of sera against E. coli lysates was performed as described in Example I. All ELISA assays, described in Example I, were performed using sera previously immunoadsorbed on E. coli lysates.
  • Sera were grouped according to reactivity by ELISA with total LFCFPs, or the sized fraction containing the 38 kDa PstS or the 88 kDa seroreactive protein (Table 10).
  • Group I includes sera from 16 PPD + and 7 PPD neg healthy controls, none of whom were positive in ELISA with any of these antigen preparations.
  • Group II includes 9 TB patients who tested antibody negative with all three antigen preparations; five of these patients were smear-positive and had cavitary disease. The remaining four patients lacked cavitary lesions, but two of these four were smear- positive.
  • Group III includes thirteen patients with antibodies to both the LFCFPs and the fraction containing the 88 kDa antigen, but not the fraction containing the 38 kDa antigen. Five of these patients were smear-positive and had pulmonary cavitations. An additional four were smear-positive but lacked any cavitary lesions. The remaining four were smear negative and had no cavitations. Group IV included eleven patients, all of whom had antibodies to all three antigen preparations; 10/11 were smear-positive and all had radiological evidence of moderate to advanced cavitary disease.
  • n number of individuals in each group
  • the 30-32 and 65 kDa antigens were also recognized by sera of the 9 PPD + healthy controls (lanes 8-16), though only 3/9 sera in this group recognized the 26 kDa antigen (lanes 8, 13 and 14), and one serum sample recognized an additional 68 kDa antigen (lane 12).
  • Lanes 17-24 show the reactivity of group II tuberculous sera, which were antibody negative with all 3 antigen preparations by ELISA. Despite some variability among individual tuberculous sera, all reacted with the 30-32 kDa and 65 kDa antigens, and 5/8 (lanes 19, 21-24) contained antibodies to the 26 kDa antigen that was also recognized by the controls. Serum from one patient (lane 21) showed strong reactivity with 46, 55 and 97 kDa antigens. Four sera, including the latter patient, showed faint reactivity with antigens of 74, 76, 88, 105 and 112 kDa antigens, and with some antigens between 46-55 kDa. Sera from patients with cavitary disease (lanes 19, 22-24) and sera from patients with no cavitations (lanes 17, 18, 20 and 21) showed no significant difference in reactivity.
  • the other two antigens reactive with all serum groups had molecular weights of 55 kDa (#114, 120) and 58 kDa (#86, 96, 105) and failed to react with any murine mAb.
  • the former antigen has been identified as the glutamine synthetase by N-group analysis (Example V, above). These antigens may correspond to the 65 kDa antigen that was reactive with the individual sera on 1-D blots.
  • a 26 kDa antigen (#19, 29) and a 46 kDa (#51) were reactive with the control sera (group I) and antibody positive TB sera (group III, Figure 18C and group IV, Figure 18D), but failed to react with the antibody negative TB serum pool (group II, Figure 18B).
  • the former antigen (26 kDa, #19, 29) was identified as MPT64 based on reactivity with the murine mAb IT- 67 and may be the 26 kDa antigen recognized by several control sera on the 1-D blots ( Figure 17, lanes 2-7, 8, 13 and 14).
  • antigens correspond to the multiple bands in the 30 to 60 kDa region on the 1-D blots.
  • a 85 kDa protein (#113, 124, IT-42, IT-57) was reactive with this serum pool, but no antigens corresponding to the 74 and 76 kDa antigens seen on 1-D blots were discernible on the 2-D blot.
  • the 85 kDa antigen (#113, 124) on the 2-D immunoblots corresponds to the 88 kDa antigen (Example I) and as seen in Figure 17 and in Example V, above).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

De nombreux antigènes de protéines et de glycoprotéines sécrétés par Mycobacterium tuberculosis (Mt) ont étés identifiés comme étant des antigènes de Mt 'précoces' du fait de la présence d'anticorps précoces chez des sujets infectés par Mt avant même que la maladie cliniquement décelable ne soit contractée. Ces antigène des Mt précoces, en particulier une protéine sécrétée de 88 kDa avec un pHi de 5,2 environ présente dans un filtrat de culture exempt de lipoarabinomannane Mt, une protéine caractérisée comme un antigène de Mt 85C, une protéine caractérisée comme un antigène de Mt MPT51, une glycoprotéine caractérisée comme un antigène de Mt MPT32, une protéine de 49 kDa avec un pHi de 5,1 environ, sont tous efficaces dans les techniques de dosages immunologiques pour le dépistage précoce et rapide de la tuberculose chez un sujet donné. L'invention décrit également des compositions antigéniques, des procédés et un nécessaire pour détecter efficacement un antigène de Mt précoce, un anticorps de Mt précoce ainsi que des complexes immunologiques de ceux-ci. Pour la première fois, il existe un marqueur de substitution permettant un dépistage peu onéreux des sujets qui présentent un haut risque d'infection par la tuberculose, en particulier les sujets infectés par le VIH-1 et d'autres sujets immunodéficients.
PCT/US1997/024189 1996-12-31 1997-12-29 Depistage precoce des maladies mycobacteriennes WO1998029132A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97954653A EP0952849A4 (fr) 1996-12-31 1997-12-29 Depistage precoce des maladies mycobacteriennes
AU59051/98A AU746752B2 (en) 1996-12-31 1997-12-29 Early detection of mycobacterial disease
CA002276491A CA2276491C (fr) 1996-12-31 1997-12-29 Depistage precoce des maladies mycobacteriennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3400396P 1996-12-31 1996-12-31
US60/034,003 1996-12-31

Publications (2)

Publication Number Publication Date
WO1998029132A1 true WO1998029132A1 (fr) 1998-07-09
WO1998029132A9 WO1998029132A9 (fr) 1998-10-29

Family

ID=21873719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/024189 WO1998029132A1 (fr) 1996-12-31 1997-12-29 Depistage precoce des maladies mycobacteriennes

Country Status (4)

Country Link
EP (1) EP0952849A4 (fr)
AU (1) AU746752B2 (fr)
CA (1) CA2276491C (fr)
WO (1) WO1998029132A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073345A2 (fr) * 1999-05-28 2000-12-07 Promega Corporation Anticorps specifiques des polypeptides mycobacteriens et leurs utilisations
WO2002050108A2 (fr) * 2000-12-21 2002-06-27 Institut Pasteur Glycopeptides immunogenes, criblage, préparation et applications.
WO2002054073A2 (fr) * 2001-01-08 2002-07-11 The Governement Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modele de tuberculose humaine latente, antigenes diagnostiques et methodes d'utilisation associees
WO2003040722A1 (fr) * 2001-11-09 2003-05-15 Kreatech Biotechnology B.V. Moyens et methodes de detection d'immunoglobuline pouvant se fixer a un antigene de mycobacterie
EP1463526A2 (fr) * 2001-08-02 2004-10-06 New York University Detection precoce de maladies mycobacteriennes au moyen de peptides
EP2006395A1 (fr) * 1998-08-25 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Différences moléculaire entre les espèces du complexe M. tuberculosis
WO2009156475A1 (fr) * 2008-06-25 2009-12-30 Justus-Liebig-Universität Giessen Procédé de dépistage spécifique d'anticorps vis-à-vis de map
WO2009129521A3 (fr) * 2008-04-19 2010-02-18 New York University Peptide de mycobacterium tuberculosis immunodominants provenant de protéines de paroi cellulaire pour un diagnostic précoce et une immunisation
US7820142B2 (en) 2004-09-30 2010-10-26 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
WO2016135384A1 (fr) 2015-02-27 2016-09-01 Tamara Tuuminen Procédé de détection de lipoarabinomannane (lam) pour dépister des infections mycobactériennes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004041A1 (fr) * 1988-10-04 1990-04-19 Dna Plant Technology Corporation Detection bacterienne par transduction de phages de phenotypes detectables
US5254459A (en) * 1990-08-23 1993-10-19 Patarroyo Manuel E Nucleotide and amino acid sequences of protein MTP40 of M. tuberculosis and synthetic peptides derived therefrom
AU9052491A (en) * 1990-11-19 1992-06-11 University Of Florida Assay device and method for antibody and antigen detection
SE9600949D0 (sv) * 1996-03-12 1996-03-12 Stefan Svenson Method of diagnosing a mycobacterial disease and immunoassay kit

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASSEY, E.O.E. CATTY, D. KUMARARATNE, D.S. RAYKUNDALIA, C.: "Candidate antigens for improved serodiagnosis of tuberculosis", TUBERCLE AND LUNG DISEASE., CHURCHILL LIVINGSTONE MEDICAL JOURNALS, EDINBURGH., GB, vol. 77, no. 2, 1 April 1996 (1996-04-01), GB, pages 136 - 145, XP004540072, ISSN: 0962-8479, DOI: 10.1016/S0962-8479(96)90028-3 *
MCDONOUGH J A, ET AL.: "Microplate and Dot Immunoassays for the Serodiagnosis of Tubercul osis", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 120, 1 August 1992 (1992-08-01), pages 318 - 322, XP002981670, ISSN: 0022-2143 *
SADA E D, FERGUSON L E, DANIEL T M: "THE JOURNAL OF INFECTIOUS DISEASES, October 1990, Vol. 162, SADA et al., An ELISA for the Serodiagnosis of Tuberculosis Using a 30,000-da Native Antigen of Mycobacterium Tuberculosis", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS., CHICAGO, IL., vol. 162, 1 October 1990 (1990-10-01), CHICAGO, IL., pages 928 - 931, XP002981669, ISSN: 0022-1899 *
See also references of EP0952849A4 *
YOUNG D B, ET AL.: "Mycobacterial Protein Antigens: A Compilation", MOLECULAR MICROBIOLOGY., WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 6, no. 2, 1 January 1992 (1992-01-01), GB, pages 133 - 145, XP002981668, ISSN: 0950-382X, DOI: 10.1111/j.1365-2958.1992.tb01994.x *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700118B2 (en) 1998-08-25 2010-04-20 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
EP2006395A1 (fr) * 1998-08-25 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Différences moléculaire entre les espèces du complexe M. tuberculosis
WO2000073345A3 (fr) * 1999-05-28 2001-05-25 Promega Corp Anticorps specifiques des polypeptides mycobacteriens et leurs utilisations
WO2000073345A2 (fr) * 1999-05-28 2000-12-07 Promega Corporation Anticorps specifiques des polypeptides mycobacteriens et leurs utilisations
FR2818647A1 (fr) * 2000-12-21 2002-06-28 Pasteur Institut Glycopeptides immunogenes, criblage, preparation et applications
WO2002050108A3 (fr) * 2000-12-21 2002-08-29 Pasteur Institut Glycopeptides immunogenes, criblage, préparation et applications.
JP2004520317A (ja) * 2000-12-21 2004-07-08 インスティティ・パスツール 免疫原性グリコペプチド、スクリーニング、製造及び使用
US7658929B2 (en) 2000-12-21 2010-02-09 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
WO2002050108A2 (fr) * 2000-12-21 2002-06-27 Institut Pasteur Glycopeptides immunogenes, criblage, préparation et applications.
US7361348B2 (en) 2000-12-21 2008-04-22 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
WO2002054073A2 (fr) * 2001-01-08 2002-07-11 The Governement Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modele de tuberculose humaine latente, antigenes diagnostiques et methodes d'utilisation associees
WO2002054073A3 (fr) * 2001-01-08 2003-08-28 Us Gov Health & Human Serv Modele de tuberculose humaine latente, antigenes diagnostiques et methodes d'utilisation associees
US7105170B2 (en) 2001-01-08 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services Latent human tuberculosis model, diagnostic antigens, and methods of use
AU2002237764B2 (en) * 2001-01-08 2007-08-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Latent human tuberculosis model, diagnostic antigens, and methods of use
EP1463526A4 (fr) * 2001-08-02 2006-08-30 Univ New York Detection precoce de maladies mycobacteriennes au moyen de peptides
AU2002324578B2 (en) * 2001-08-02 2009-02-05 Colorado State University Research Foundation Early detection of mycobacterial disease using peptides
EP1463526A2 (fr) * 2001-08-02 2004-10-06 New York University Detection precoce de maladies mycobacteriennes au moyen de peptides
WO2003040722A1 (fr) * 2001-11-09 2003-05-15 Kreatech Biotechnology B.V. Moyens et methodes de detection d'immunoglobuline pouvant se fixer a un antigene de mycobacterie
US7820142B2 (en) 2004-09-30 2010-10-26 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
WO2009129521A3 (fr) * 2008-04-19 2010-02-18 New York University Peptide de mycobacterium tuberculosis immunodominants provenant de protéines de paroi cellulaire pour un diagnostic précoce et une immunisation
WO2009156475A1 (fr) * 2008-06-25 2009-12-30 Justus-Liebig-Universität Giessen Procédé de dépistage spécifique d'anticorps vis-à-vis de map
WO2016135384A1 (fr) 2015-02-27 2016-09-01 Tamara Tuuminen Procédé de détection de lipoarabinomannane (lam) pour dépister des infections mycobactériennes

Also Published As

Publication number Publication date
CA2276491A1 (fr) 1998-07-09
CA2276491C (fr) 2008-01-22
EP0952849A1 (fr) 1999-11-03
AU5905198A (en) 1998-07-31
EP0952849A4 (fr) 2004-09-08
AU746752B2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
US6506384B1 (en) Early detection of mycobacterial disease
US6245331B1 (en) Early detection of mycobacterial disease
US7776341B2 (en) Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
DK2417456T3 (en) DIAGNOSTIC TEST Mycobacterium tuberculosis
KR20010012813A (ko) 결핵 확인용 화합물 및 이의 사용 방법
Roche et al. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis
MXPA01004469A (es) Prueba de diagnostico para la tuberculosis.
US7745141B2 (en) Mycobacterial proteins as early antigens for serodiagnosis and vaccines
AU746752B2 (en) Early detection of mycobacterial disease
De Kesel et al. Composition and immunological properties of the protein fraction of A36, a major antigen complex of Mycobacterium paratuberculosis
US9335325B2 (en) Immunodominant Mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
AU2002324578B2 (en) Early detection of mycobacterial disease using peptides
WO1998029132A9 (fr) Depistage precoce des maladies mycobacteriennes
AU2002324578A1 (en) Early detection of mycobacterial disease using peptides
US7807182B2 (en) Early detection of mycobacterial disease using peptides
Le Moigne et al. Expression, immunochemical characterization and localization of the Mycobacterium tuberculosis protein p27
JP6698530B2 (ja) インビボまたはインビトロでの細胞が介在する結核の免疫学的診断の改善のための診断試薬
US8470339B2 (en) Antigens for paratuberculosis diagnosis and vaccination
Falla et al. Identification of B-and T-cell epitopes within the MTP40 protein of Mycobacterium tuberculosis and their correlation with the disease course
Belisle et al. The proteome of Mycobacterium tuberculosis
Gilot et al. Thermostable macromolecular antigens from mycobacteria
WO2008010096A2 (fr) Procédé de préparation de polypeptides mycobactériens recombinés de levure et leur utilisation pour diagnostiquer des maladies associées à des mycobactéries
Sartain Evaluation and characterization of tuberculosis serodiagnostic biomarkers
McGill Characterization of humoral immune responses against Treponema pallidum antigens
EA041840B1 (ru) Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/32-32/32; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2276491

Country of ref document: CA

Ref country code: CA

Ref document number: 2276491

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 59051/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997954653

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997954653

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 59051/98

Country of ref document: AU